

Patient characteristics and prescription patterns of atyp with schizophrenia

Journal of Clinical Pharmacy and Therapeutics

27, 441-451

DOI: [10.1046/j.1365-2710.2002.00443.x](https://doi.org/10.1046/j.1365-2710.2002.00443.x)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 471-481.	0.7	7
3	Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 513-522.	0.8	47
4	Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 487-495.	2.5	12
5	Risperidone versus olanzapine for schizophrenia. , 2005, , CD005237.		9
6	Choice of atypical antipsychotic therapy for patients with schizophrenia: An analysis of a medicaid population. <i>Current Therapeutic Research</i> , 2005, 66, 463-474.	0.5	3
7	Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia. <i>Schizophrenia Research</i> , 2005, 77, 167-177.	1.1	7
8	The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1442-1452.	2.5	18
9	Risperidone versus olanzapine for schizophrenia. <i>The Cochrane Library</i> , 2006, , CD005237.	1.5	42
10	Dissemination of Methods and Results From the Veterans Health Study. <i>Journal of Ambulatory Care Management</i> , 2006, 29, 310-319.	0.5	112
11	Medication effectiveness studies in the United States Veterans Administration health care system: a model for large integrated delivery systems. <i>Drug Development Research</i> , 2006, 67, 217-226.	1.4	22
12	The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2007, 34, 307-314.	1.2	31
13	Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. <i>Patient Preference and Adherence</i> , 2008, 2, 67.	0.8	54
14	Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. <i>Cost Effectiveness and Resource Allocation</i> , 2009, 7, 4.	0.6	37
15	Patterns of clozapine prescribing in a mental health service in New Zealand. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 503-511.	1.4	35
16	The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. <i>International Journal of Methods in Psychiatric Research</i> , 2010, 19, 195-210.	1.1	27
17	Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. <i>BMC Psychiatry</i> , 2011, 11, 87.	1.1	11
18	Antipsychotic Prescribing Pathways, Polypharmacy, and Clozapine Use in Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2013, 64, 527-533.	1.1	59
19	Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China. <i>BMC Health Services Research</i> , 2015, 15, 149.	0.9	3

#	ARTICLE	IF	CITATIONS
20	Schizophrenia and Depression: A systematic Review of the Effectiveness and the Working Mechanisms Behind Acupuncture. <i>Explore: the Journal of Science and Healing</i> , 2015, 11, 281-291.	0.4	30
21	Acupuncture as Add-On Treatment of the Positive, Negative, and Cognitive Symptoms of Patients with Schizophrenia: A Systematic Review. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 29.	0.7	11
22	Oral antipsychotic prescribing and association with neighbourhood-level socioeconomic status: analysis of time trend of routine primary care data in England, 2011â€”2016. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 165-173.	1.6	5
23	Prescription Pattern of Antipsychotics Polypharmacy in patients with Schizophrenia in an Indian Hospital. <i>Research Journal of Pharmacy and Technology</i> , 2021, , 4265-4269.	0.2	1
24	An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 277-284.	1.0	3
25	Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008, 2, 226-234.	1.4	5
26	Characteristics of Outpatients Initiated on Olanzapine versus Risperidone in the Treatment of Schizophrenia in Japan: A Healthcare Database Analysis. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2011, 2, 1-8.	0.3	3
27	Ethnic disparities in clozapine prescription for service-users with schizophrenia-spectrum disorders: a systematic review. <i>Psychological Medicine</i> , 2022, 52, 2212-2223.	2.7	7